Vertex secures two FDA wins for cystic fibrosis, both with boxed ...
5 days ago · Cystic fibrosis is a life-threatening genetic disorder that causes sticky mucus to build up in the lungs and digestive system. Credit: Iren_Geo via Shutterstock. Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments ...
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily …
Dec 20, 2024 · The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in …
Vertex Announces US FDA Approval of ALYFTREK - Business Wire
Dec 20, 2024 · ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis ...
Vertex Announces U.S. FDA Approval for TRIKAFTA …
Dec 20, 2024 · “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “With this approval, even more patients may be able to benefit from ...
Vertex wins FDA nod for once-daily cystic fibrosis triplet
5 days ago · The FDA has approved Vertex’s Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis in people 6 years and older who have mutations that are amenable to the therapy, the ...
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
5 days ago · Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be...
Vertex Announces US FDA Approval of ALYFTREK™, a Once
6 days ago · Learn more about the importance of sweat chloride (SwCl) in cystic fibrosis. Today Vertex CF medicines are treating over 68,000 people with CF across more than 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy. ... BioSpace is the digital hub for life science news and jobs ...
Vertex wins Trikafta expansion and approval for 'vanza triple' once ...
5 days ago · Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data …
Sep 26, 2024 · Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years taking TRIKAFTA ®, demonstrating consistent and sustained improvements across multiple measures of disease.
News & Events - Vertex Pharmaceuticals
Jul 2, 2024 · The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in …
- Some results have been removed